Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Mar 27, 2026; 18(3): 114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569
Table 2 Comparative assessment of clinical response, n (%)
| Response evaluation | Control group (n = 60) | Research group (n = 64) | χ2 | P value |
| Complete response | 11 (18.33) | 17 (26.56) | ||
| Partial response | 27 (45.00) | 28 (43.75) | ||
| Stable disease | 8 (13.33) | 11 (17.19) | ||
| Progressive disease | 14 (23.33) | 8 (12.50) | ||
| Tumor control | 46 (76.67) | 56 (87.50) | 2.490 | 0.115 |
- Citation: Shi JF, Xu H, Gao JF, Wu JB. Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation. World J Gastrointest Surg 2026; 18(3): 114569
- URL: https://www.wjgnet.com/1948-9366/full/v18/i3/114569.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v18.i3.114569